Mostrar el registro sencillo del ítem
dc.contributor.author
Molina, Luis
dc.contributor.author
Recinos, Byron
dc.contributor.author
Paz, Bezner
dc.contributor.author
Rovelo, Mauricio
dc.contributor.author
Elias Rodriguez, Fanny Elizabeth
dc.contributor.author
Calderón, José
dc.contributor.author
Arellano, Arturo
dc.contributor.author
Pomata, Santiago
dc.contributor.author
Rey, María Verónica
dc.contributor.author
Pérez Lloret, Santiago
dc.date.available
2018-04-11T21:10:48Z
dc.date.issued
2016-03
dc.identifier.citation
Molina, Luis; Recinos, Byron; Paz, Bezner; Rovelo, Mauricio; Elias Rodriguez, Fanny Elizabeth; et al.; Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study; Springer; Clinical Drug Investigation; 36; 6; 3-2016; 491-497
dc.identifier.issn
1173-2563
dc.identifier.uri
http://hdl.handle.net/11336/41808
dc.description.abstract
Background and Objectives
The first weeks of treatment with antipsychotics are important for the development of their long-term efficacy. The objective of this study was to identify factors related to early clinical effects and quality of life (QoL) improvements with quetiapine extended-release (XR).
Methods
Six hundred and sixty-five patients starting with quetiapine XR were followed up for 8 weeks (schizophrenia = 153, major depression = 200, bipolar depression = 252, other psychiatric conditions = 60). Clinical effects were assessed by the Clinical Global Impression of Change scale (CGI-C), QoL by the visual analog scale (VAS) of the EQ-5D (QoL-VAS), and adherence by the Moriksy scale. Adverse events were explored: movement disorders by the UKU and Simpson-Angus scales, weight gain by calibrated balances, and diurnal somnolence by the Epworth Somnolence Scale (ESS).
Results
The mean dose of quetiapine XR during follow-up was 195.6 ± 154.8 mg/day. CGI and QoL-VAS scores improved significantly at week 8 by 2.7 ± 0.1 points and 25.1 ± 0.9 points. Adverse events were observed in 34 and 26 % of patients at weeks 4 and 8, respectively. A significant reduction in ESS score was also observed at week 8. Factors independently associated with change in QoL-VAS ≥20 points (n = 292, 43 %) were female gender, more severe disease at baseline, higher antipsychotic dose during follow-up, and improvements in somnolence. Factors independently associated with clinically significant improvement (CGI-C ≥5, n = 610, 93 %) were greater change in QoL-VAS, less frequent movement disorders at baseline, and lack of adverse events during follow-up, especially somnolence.
Conclusions
Results from this real-setting, large observational study in Central America suggest that disease severity at baseline, gender, antipsychotic dose, and occurrence of adverse reactions has a significant impact on the early clinical effects of quetiapine XR.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Springer
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
Ezquisofrenia
dc.subject
Depresion
dc.subject
Quetipina
dc.subject
Efectos Tempranos
dc.subject.classification
Medicina Critica y de Emergencia
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Factors Related to Early Clinical Effects of Quetiapine Extended-Release: A Multinational, Prospective, Observational Study
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2018-04-10T20:29:08Z
dc.journal.volume
36
dc.journal.number
6
dc.journal.pagination
491-497
dc.journal.pais
Alemania
dc.journal.ciudad
Berlín
dc.description.fil
Fil: Molina, Luis. Clínica de Especialidades Altamira; Nicaragua
dc.description.fil
Fil: Recinos, Byron. Universidad San Carlos de Guatemala; Guatemala
dc.description.fil
Fil: Paz, Bezner. Hospital Juan de Dios de San Pedro; Honduras
dc.description.fil
Fil: Rovelo, Mauricio. Instituto de Salud Mental; Honduras
dc.description.fil
Fil: Elias Rodriguez, Fanny Elizabeth. Colonia Médica; El Salvador
dc.description.fil
Fil: Calderón, José. Clínica de la Conducta; Panamá
dc.description.fil
Fil: Arellano, Arturo. Corporación Farmacéutica Recalcine; Costa Rica
dc.description.fil
Fil: Pomata, Santiago. Corporación Farmacéutica Recalcine; Costa Rica
dc.description.fil
Fil: Rey, María Verónica. Etymos Consulting Group; Argentina
dc.description.fil
Fil: Pérez Lloret, Santiago. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Cardiológicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Cardiológicas; Argentina
dc.journal.title
Clinical Drug Investigation
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://link.springer.com/article/10.1007%2Fs40261-016-0395-x
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1007/s40261-016-0395-x
Archivos asociados